Carmat (ALCAR PA) stock market data APIs
€0.0984
0(0%)
as of January 16, 2026
Try our APIs with
free plan!
Carmat Financial Data Overview
Price chart is built with
Anychart
Carmat SA designs and develops total artificial heart for patients with advanced heart failure in France and internationally. The company offers Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.
Prev. Close
0.0984
Open
0.0999
High
0.1103
Low
0.0962
52 wk Range
0.085-1.14
Market Cap
6 365 K
Shares Outstanding
64 254 K
Revenue
7 344 K
EPS
0
Beta
1.102
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Carmat data using free add-ons & libraries
Get Carmat Fundamental Data
Carmat Fundamental data includes:
- Net Revenue: 7 344 K
- EBITDA: -47 230 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-12-12
- EPS/Forecast: -0.13
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Carmat News
New
Carmat files for insolvency amid cash crunch
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dive Brief: Artificial heart company Carmat has filed fo...
CARMAT Achieves a Pivotal Year in 2023 by Reaching the Milestone of 50 Implants of the Aeson® Artificial Heart and Presents Its Development Prospects
50 patients have benefited from CARMAT's Aeson® artificial heart since the first implant in 2013 Aeson® becomes an essential breakthrough innovation in the treatment of advanced biventricular heart ...
CARMAT announces a conditional agreement in principle with the EIB on new loan repayment terms, as part of the management of its short-term financing challenge
The implementation of this agreement would lead to a significant extension of the maturity date of each of three tranches of the loan Extension of the maturity date of the first tranche of the loan (...
CARMAT Announces the Approval of All Resolutions Supported by the Board of Directors at its Extraordinary General Meeting
PARIS, January 05, 2024--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of Aeson®, the world’s most advanced total artificial heart, aiming to provide a the...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
